Generalized Anxiety Disorder (GAD) & Panic Disorder

An authoritative clinical profile of Generalized Anxiety Disorder covering APA 2020 guidelines, autonomic GABA/serotonergic neuro-pathways, psychiatric crisis emergency red flags, and psychotropic non-discontinuation boundaries.

Editorial review complete

Independent clinical validation is pending.

Validation pending

Quick Reference Facts

System AffinityGeneral
Diagnostic StandardClinical evaluation & serum biomarkers
Urgency Levelroutine
Evidence GradeConsensus-Guidance

Evidence Summary

Body SystemClinical Medicine
Typical PrevalenceClinical review pending
Typical Age RangeClinical review pending
Clinical Urgencyroutine
Primary Etiological Factors
  • Dysregulated amygdala-prefrontal neural circuitry and altered GABAergic, serotonergic, and noradrenergic neurotransmission [D0019-KEYNOTES, CIT-0050]
  • Genetic heritability interacting with adverse childhood experiences, chronic psychogenic stress, or trauma
  • Somatic medical conditions (hyperthyroidism, pheochromocytoma, cardiac dysrhythmias) or caffeine/stimulant overuse
Recommended Screenings
Diagnosed via DSM-5-TR or ICD-11 clinical criteria

Disease Progression Timeline

Stage 1 of 6

Risk Factors & Triggers

Underlying clinical predispositions, familial autoimmune markers, genetic anomalies, or environmental catalysts that establish susceptibility.

Clinical Pearl: Early screening of relatives with similar patterns is highly recommended.

Clinical Overview

Generalized Anxiety Disorder (GAD) is characterized by excessive, uncontrollable worry and anxiety about everyday events lasting ≥6 months, accompanied by somatic autonomic symptoms [D0019-KEYNOTES, CIT-0050]. APA 2020 recommends integrated psychological and pharmacological care.

Clinical Definition

A psychiatric disorder characterized by pervasive, persistent, and unprovoked worry, motor tension, autonomic hyperactivity, and cognitive hypervigilance.

Pathological Causes

  • Dysregulated amygdala-prefrontal neural circuitry and altered GABAergic, serotonergic, and noradrenergic neurotransmission [D0019-KEYNOTES, CIT-0050]
  • Genetic heritability interacting with adverse childhood experiences, chronic psychogenic stress, or trauma
  • Somatic medical conditions (hyperthyroidism, pheochromocytoma, cardiac dysrhythmias) or caffeine/stimulant overuse

Risk Factors

  • Family history of anxiety, depression, or neuroatopic diathesis
  • Female sex, chronic physical illness, low social support, and personality traits (neuroticism)
  • Abrupt withdrawal from benzodiazepines, alcohol, or sedatives

Clinical Symptom Presentation

  • Restlessness, feeling keyed up or on edge, muscle tension, and easy fatigability [D0019-KEYNOTES, CIT-0050]
  • Difficulty concentrating, irritability, sleep-onset insomnia, and unrefreshing sleep
  • Autonomic hyperactivity: Palpitations, diaphoresis, tremors, shortness of breath, epigastric distress, and dizziness

Diagnostic Evaluation

Investigation Protocol

Diagnosed via DSM-5-TR or ICD-11 clinical criteria, GAD-7 psychometric rating scale, and laboratory screening (TSH, CBC, serum electrolytes, ECG) to exclude organic endocrine/cardiac causes [CIT-0050].

Differential Diagnosis

Differentiate GAD from Panic Disorder, Major Depressive Disorder, Hyperthyroidism, Hypoglycemia, Pheochromocytoma, and Acute Coronary Syndrome (ACS during panic attack).

Differential Diagnosis Matrix

Differential Diagnosis Overview

Differentiate GAD from Panic Disorder, Major Depressive Disorder, Hyperthyroidism, Hypoglycemia, Pheochromocytoma, and Acute Coronary Syndrome (ACS during panic attack).

Treatment Approaches

Conventional Management

Management includes Cognitive Behavioral Therapy (CBT), selective serotonin reuptake inhibitors (SSRIs - escitalopram, sertraline), serotonin-norepinephrine reuptake inhibitors (SNRIs - duloxetine, venlafaxine), or short-term buspirone/pregabalin [CIT-0050].

Homeopathic Approach

Homeopathic remedies (such as Aconitum Napellus, Argentum Nitricum, Arsenicum Album, Gelsemium, Ignatia) serve as supportive constitutional care to calm autonomic over-arousal, ease anticipatory dread, and improve sleep latency alongside professional psychiatric evaluation.

Lifestyle & Diet Advice

Engage in daily diaphragmatic breathing and mindfulness meditation, reduce caffeine and alcohol intake, maintain regular sleep hygiene, and perform moderate aerobic exercise.

Reference Citations & Evidence Sources

Clinical Guidelines & Consensus Statements
  • CIT-0050American Psychiatric Association. "APA Clinical Practice Guideline for the Treatment of Generalized Anxiety Disorder in Adults." APA Practice Guidelines (2020).DOI PubMed
Materia Medica & Keynotes
  • CIT-0004Hahnemann S.. "Materia Medica Pura." Adolph Arnold (1811).
  • CIT-0005Kent J. T.. "Lectures on Homoeopathic Materia Medica." Boericke & Tafel (1905).
  • CIT-0006Boericke W.. "Pocket Manual of Homoeopathic Materia Medica." Boericke & Runyon (1901).

AI & Generative Search Citation Block

Entity IDD0019
Entity Typedisease
Content Versionv1.1.0
Last Reviewed DateJul 31, 2026
Evidence LevelConsensus-Guidance
Suggested Academic/LLM Citation format (AMA Style)

Dr. Narayan Jethwani. "Generalized Anxiety Disorder (GAD) & Panic Disorder." Homeo Healthcare Clinical Platform. Version 1.1.0. Reviewed: 2026-07-31T12:00:00Z. Available at: https://homeo.healthcare/knowledge/diseases/anxiety-disorder

No clinical connections registered for this topic.

Medical Safety Disclaimer

All content on the Homeo Healthcare platform is strictly for educational purposes and is not personal medical advice, diagnosis, or treatment. Homeopathic remedy considerations are provided for clinician review or require individualized consultation with a qualified physician. Never delay seeking professional medical advice or emergency medical care due to content you have read on this website.